Healthcare
DiaMedica Therapeutics Inc.(DMAC)
Live Price
Offline$5.85
+2.09% today
1Y Change
+58.99%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $340.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -16.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DiaMedica Therapeutics Inc. (DMAC) is a Healthcare stock with a market cap of $340.00M and listed on NASDAQ. The stock last traded around $5.85 and up 59.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -16.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -16.7%, free cash flow -31.7% with operating margin 0.0% and ROIC -61.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DMAC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -16.7%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -0.9% | -11.9% | -15.7% |
2026 Mar 30, 2026 | +0.0% | +2.0% | -1.4% | -6.3% |
2025 Nov 12, 2025 | -13.3% | -14.1% | +15.7% | +48.0% |
Benchmark Edge
DMAC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DMAC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DMAC Max Drawdown
-43.24%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DMAC and SPY.
Company Overview
DiaMedica Therapeutics Inc.
NASDAQ Capital Market
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Leadership
- Dietrich John Pauls
- IPO Date
- Aug 3, 2012
- Employees
- 27
- Street Address
- Two Carlson Parkway
- Mailing
- Minneapolis, MN, 55447
- Region
- Minneapolis, MN, US
- Reporting Currency
- USD
- Investor Line
- 763 612 6755
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.2
Growth
- Revenue
- 0.0%
- EPS
- -16.7%
- Free Cash Flow
- -31.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -77.6%
- ROIC
- -61.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 11.81
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.